Arcus Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Arcus Biosciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Arcus is a focused immuno-oncology player with differentiated ATP-adenosine pathway expertise and multiple Phase 3 programs providing multiple near-term catalysts. The company has a robust pipeline with multiple clinical-stage candidates including Domvanalimab (Phase 2/3) and Quemliclustat (Phase 3) in advanced development. Strong financial position with a debt-to-equity ratio of.
What is Arcus Biosciences, Inc.'s industry? Arcus Biosciences, Inc. (arcusbio.com) operates in Biopharmaceutical - Immuno-oncology & Cancer Therapeutics. AskCyborg classifies Arcus Biosciences, Inc. under Biopharmaceutical - Immuno-oncology & Cancer Therapeutics in its company registry.
Arcus Biosciences is a clinical-stage biopharmaceutical company that develops and commercializes cancer therapies in the United States. The company's strategic focus is on targeting well-understood biological pathways...
Cyborg Score thesis
Arcus is a focused immuno-oncology player with differentiated ATP-adenosine pathway expertise and multiple Phase 3 programs...
Read the full analyst-debate transcript →Get the Latest Arcus Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeArcus Biosciences, Inc. Overview
Pro stress-test →Arcus Biosciences is a clinical-stage biopharmaceutical company that develops and commercializes cancer therapies in the United States. The company's strategic focus is on targeting well-understood biological pathways where there is a significant opportunity to create novel therapies with improved safety and efficacy profiles, leveraging scientific expertise to design best-in-class molecules and combination therapies.
Strategic Profile
Pro stress-test →Arcus focuses on the ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment, to create and optimize differentiated small-molecule immuno-oncology product candidates. The company's main offerings include development of potential cancer therapies, with particular emphasis on creating combination treatments. 2026 company priorities include rapid enrollment in the PEAK-1 Phase 3 study and initiating a first-line Phase 3 trial in kidney cancer.
Competitive Landscape
Pro stress-test →Top competitors include Gritstone Bio, Sorrento Therapeutics, Iovance Biotherapeutics, and Avid Bioservices. Arcus differentiates through focused ATP-adenosine pathway expertise and emphasis on combination therapies to address immunosuppression in tumor microenvironment.
Industry Context
Arcus Biosciences, Inc. operates in Biopharmaceutical - Immuno-oncology & Cancer Therapeutics.
Key facts
Founded: 2015 · Headquarters: Hayward, California · Revenue: $240M · Market cap: $2.5B